Atrasentan is approved for proteinuria reduction in primary IgA nephropathy, a condition risking kidney failure. The phase 3 ALIGN study showed atrasentan reduced proteinuria by 36.1% compared to ...

Atrasentan reduced urine protein-to-creatinine ratio by 38% compared with 3% for placebo at week 36. The Food and Drug Administration (FDA) has granted accelerated approval to Vanrafia ...

is in the Limited Distribution Network for Vanrafia ™ (atrasentan), for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) and are at risk of rapid disease ...